



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 87666

**Title:** Metabolomics in Chronic Hepatitis C: Decoding Fibrosis Grading and Underlying Pathways

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 04025443

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Doctor, Senior Researcher

**Reviewer's Country/Territory:** Russia

**Author's Country/Territory:** Brazil

**Manuscript submission date:** 2023-08-22

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-08-30 09:20

**Reviewer performed review:** 2023-08-30 11:52

**Review time:** 2 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input checked="" type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input checked="" type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

Dear colleagues! I read with interest your manuscript "Metabolomics in Chronic Hepatitis C: Decoding Fibrosis Grading and Underlying Pathways", which is based on the original research. There are some major problems that does not allow to recommend the manuscript for publishing. 1. There is no description of the studied group (age, gender, BMI, disease duration, necroinflammatory activity, presence and grade of liver steatosis, habits of the subjects, their diet etc). As this information is lacking, the data cannot be reproducible. 2. There is a great number of factors (beside mentioned above) that can have an impact on the metabolite's profile in the subjects. A number of the confounders requires the greater sample size to enhance statistical power. 3. It is not clear, how fibrosis stage was established. In case of liver biopsy - what is the time between liver biopsy and taking a blood samples for metabolic profiling? 4. Selection criteria are not mentioned. Did you applied some? 5. The control group is lacking. This does not allow to judge whether variability may occur in "healthy" population 6. Conclusions are too vague and are not based on the results of the study. As the number of flaws is too high and some of them may hardly be fixed, I cannot recommend this



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

manuscript for publishing. However, I hope that my comments will help you to plan further studies.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 87666

**Title:** Metabolomics in Chronic Hepatitis C: Decoding Fibrosis Grading and Underlying Pathways

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 04072104

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Chief Doctor, Doctor, Occupational Physician, Research Scientist

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Brazil

**Manuscript submission date:** 2023-08-22

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2023-08-29 13:24

**Reviewer performed review:** 2023-09-05 13:07

**Review time:** 6 Days and 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Novelty of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
<b>Creativity or innovation of this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation



<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

It is an interesting manuscript about “Metabolomics in Chronic Hepatitis C: Decoding Fibrosis Grading and Underlying Pathways” My concern is determined in the following points. Some of the observed biomarkers, once validated, have the potential for application as prognostic biomarkers. Analyses based on liquid biopsy are quite less invasive, and blood plasma, once circulates through the whole body, contains biomarker representative of pathologies that have not yet manifested clinically. It is easier to understand if authors explain with a case example. Multisegment injection-capillary electrophoresis-mass spectrometry (MSI-CE-MS) and nuclear magnetic resonance (NMR) spectroscopy for characterizing the serum metabolome of patients with liver fibrosis in chronic hepatitis C virus (HCV) infection: both instrumental techniques enable rapid yet reliable quantification of serum metabolites in large-scale metabolomic studies with good overlap for biomarker replication. Advantages of MSI-CE-MS include greater metabolome coverage, lower operating costs, and smaller sample volume requirements, whereas NMR offers a robust platform supported by automated spectral and data processing software. Above mentioned methods associated with metabolomics should



# Baishideng Publishing Group

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

be referred to.